ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

被引：0
|
作者：
Susanna Slater
Annette Bryant
Hsiang-Chi Chen
Ruwaida Begum
Isma Rana
Maria Aresu
Clare Peckitt
Oleg Zhitkov
Retchel Lazaro-Alcausi
Victoria Borja
Rachel Powell
David Lowery
Michael Hubank
Thereasa Rich
Gayathri Anandappa
Ian Chau
Naureen Starling
David Cunningham
机构：
[1] Royal Marsden Hospital NHS Foundation Trust,
[2] Biomedical Research Centre at the Royal Marsden and the Institute of Cancer Research,undefined
[3] Centre for Molecular Pathology at the The Royal Marsden Hospital and Institute of Cancer Research,undefined
[4] Guardant Health,undefined
[5] INC,undefined
来源：
BMC Cancer | / 23卷
关键词：
Colorectal cancer; ctDNA; Adjuvant chemotherapy; Randomised; Disease free survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor
    Peng, Wei
    Dai, Jing
    Liu, Chao-chan
    Liu, Dian
    Xiao, Hua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial
    Matsuda, Chu
    Ishiguro, Megumi
    Teramukai, Satoshi
    Kajiwara, Yoshiki
    Fujii, Shoichi
    Kinugasa, Yusuke
    Nakamoto, Yoshihiko
    Kotake, Masanori
    Sakamoto, Yoshiyuki
    Kurachi, Kiyotaka
    Maeda, Atsuyuki
    Komori, Koji
    Tomita, Naohiro
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Kotake, Kenjiro
    Watanabe, Masahiko
    Mochizuki, Hidetaka
    Nakagawa, Yoko
    Sugihara, Kenichi
    EUROPEAN JOURNAL OF CANCER, 2018, 96 : 54 - 63
  • [33] Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial
    Ruzzo, A.
    Galli, F.
    Galli, F.
    Rulli, E.
    Lonardi, S.
    Zagonel, V.
    Ronzoni, M.
    Ionta, M. T.
    Pella, N.
    Mucciarini, C.
    Labianca, R.
    Veltri, E.
    Sozzi, P.
    Barni, S.
    Nicolini, M.
    Biondi, E.
    Bramati, A.
    Turci, D.
    Buscaglia, M.
    Magnani, M.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2017, 28 : 4 - 5
  • [34] Usefulness of the Preoperative Administration of Tegafur Suppositories as Alternative Adjuvant Chemotherapy for Patients with Resectable Stage II or III Colorectal Cancer: A KODK4 Multicenter Randomized Control Trial
    Okabayashi, Koji
    Hasegawa, Hirotoshi
    Watanabe, Masahiko
    Ohishi, Takashi
    Hisa, Akio
    Kitagawa, Yuko
    ONCOLOGY, 2012, 83 (01) : 16 - 23
  • [35] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Oh, Hyeon Jeong
    Bae, Jeong Mo
    Wen, Xianyu
    Jung, Seorin
    Kim, Younghoon
    Kim, Kyung Ju
    Cho, Nam-Yun
    Kim, Jung Ho
    Han, Sae-Won
    Kim, Tae-You
    Kang, Gyeong Hoon
    BRITISH JOURNAL OF CANCER, 2019, 120 (08) : 797 - 805
  • [36] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Hyeon Jeong Oh
    Jeong Mo Bae
    Xianyu Wen
    Seorin Jung
    Younghoon Kim
    Kyung Ju Kim
    Nam-Yun Cho
    Jung Ho Kim
    Sae-Won Han
    Tae-You Kim
    Gyeong Hoon Kang
    British Journal of Cancer, 2019, 120 : 797 - 805
  • [37] Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
    Sasako, Mitsuru
    Sakuramoto, Shinichi
    Katai, Hitoshi
    Kinoshita, Taira
    Furukawa, Hiroshi
    Yamaguchi, Toshiharu
    Nashimoto, Atsushi
    Fujii, Masashi
    Nakajima, Toshifusa
    Ohashi, Yasuo
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4387 - 4393
  • [38] Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study
    Baretti, M.
    Giordano, L.
    Rimassa, L.
    Tronconi, M. C.
    Pressiani, T.
    Bozzarelli, S.
    Personeni, N.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Greil, R.
    Tschmelitsch, J.
    Steger, G.
    Jakesz, R.
    Gnant, M.
    Hofbauer, F.
    Rabl, H.
    Thaler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer (vol 33, pg 57, 2022)
    Novello, S.
    Torri, V.
    Grohe, C.
    Kurz, S.
    Serke, M.
    Wehler, T.
    Meyer, A.
    Ladage, D.
    Geissler, M.
    Colantonio, I.
    Cauchi, C.
    Stoelben, E.
    Ceribelli, A.
    Kropf-Sanchen, C.
    Valmadre, G.
    Borra, G.
    Schena, M.
    Morabito, A.
    Santo, A.
    Gregorc, V.
    Chiari, R.
    Reck, M.
    Schmid-Bindert, G.
    Folprecht, G.
    Griesinger, F.
    Follador, A.
    Pedrazzoli, P.
    Bearz, A.
    Caffo, O.
    Dickgreber, N. J.
    Irtelli, L.
    Wiest, G.
    Monica, V.
    Porcu, L.
    Manegold, C.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2022, 33 (04) : 454 - 454
12345